Publication shows utility of ogm in solid tumor research with study on detection of complex genomic rearrangements in prostate cancer

San diego, nov. 21, 2022 (globe newswire) -- bionano genomics, inc. (nasdaq: bngo) today announced the publication of a study utilizing optical genome mapping (ogm) to detect structural variants (svs) and balanced rearrangements relevant to prostate cancer (pca) pathogenesis. ogm identified svs in all samples, potentially improving the success rate for finding pathogenic variants and streamlining the detection process.
BNGO Ratings Summary
BNGO Quant Ranking